查詢結果分析
相關文獻
- Circulating Intercellular Adhesion Molecule-1 in Chronic Liver Disease and Hepatocellular Carcinoma
- 在臺灣控制肝細胞癌及肝硬化盛行有關的研究與措施及其成效
- 以免疫病理學研究HBsAg 與HBcAg 在B 型病毒肝炎, 肝硬化及肝細胞癌之表現
- Lymphoepithelioma-Like Hepatocellular Carcinoma
- Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody
- Virological Response and Clinical Events in Patients with Chronic Hepatitis B Treated with Nucleotide Analogue
- 後病毒性肝炎時代的新挑戰--非酒精性脂肪肝病病程進展與處置
- 非酒精性脂肪肝病引起之肝細胞癌:現有及新興治療的安全性及效力
- A Survey on the Prevalence of Hepatocellular Carcinoma and Hepatitis B Virus Infection in Peng-Hu, Taiwan
- B 型肝炎病毒在肝細胞癌中所扮演之角色
頁籤選單縮合
題 名 | Circulating Intercellular Adhesion Molecule-1 in Chronic Liver Disease and Hepatocellular Carcinoma=第一型細胞間黏著分子在慢性肝病與肝細胞癌之研究 |
---|---|
作 者 | 黃以信; 吳肇卿; 陳祖裕; 趙毅; 張扶陽; 李壽東; | 書刊名 | 中華醫學雜誌 |
卷 期 | 62:8 1999.08[民88.08] |
頁 次 | 頁487-495 |
分類號 | 415.53 |
關鍵詞 | 慢性肝病; 肝炎; 肝細胞癌; 細胞間黏著分子; 肝硬化; Chronic liver disease; Hepatitis; Hepatocellular carcinoma; Intercellular adhesion molecule-1; Liver cirrhosis; |
語 文 | 英文(English) |
英文摘要 | BACKGROUND: Intercellular adhesion molecule-1 (ICAM-1) is important in the migration and adhesion of immune cells from the circulation to their targets. A circulating form of ICAM-1 (cICAM-1) is elevated in the serum of patients with hepatitis and various cancers. Our aim was to determine the clinical significance of cICAM-1 in chronic liver diseases and hepatocellular carcinoma (HCC). METHODS: We measured the serum cICAM-1 levels in 91 patients with HCC, 47 with liver cirrhosis, 41 with chronic viral hepatitis and 32 healthy controls using an enzyme-linked immunosorbent assay. Ninety-eight patients had serial follow-up. RESULTS: The cICAM-1 levels in patients with HCC (737 +/- 212 ng/ml) and liver cirrhosis (593 +/- 145 ng/ml) were significantly higher than those in patients with chronic viral hepatitis (488 +/- 127 ng/ml) and controls (318 +/- 64 ng/ml). HCC patients had higher cICAM-1 levels than all the other groups. cICAM-1 levels in patients with chronic viral hepatitis correlated with serum alanine aminotransferase, prothrombin time and indocyanine green retention ratio. In HCC patients, alpha- fetoprotein levels and tumor size paralleled cICAM-1 concentrations. Furthermore, HCC patients with distant metastases had higher cICAM-1 levels than those without distant metastases, and levels of cICAM-1 in patients with stage IV HCC were higher than those in HCC patients with stages I, II or III disease. During a seven-year follow- up, 14 patients with chronic hepatitis developed liver cirrhosis when their cICAM-1 levels increased significantly. In 47 HCC patients, cICAM-1 levels decreased after tumor resection or transcatheter arterial embolization, and increased when the tumor recurred. cICAM-1 levels increased gradually in 14 patients with advanced HCC without specific therapy. CONCLUSIONS: CICAM-1 levels are increased in patients with chronic hepatitis, liver cirrhosis and HCC. This reflects the severity and progression of chronic liver disease and HCC. Sequential measurements of cICAM-1 seem more valuable than a single-point assessment in evaluating the progress of liver disease. |
本系統中英文摘要資訊取自各篇刊載內容。